Teva, Mylan, Dr. Reddy's Launch Clopidogrel Tablets
Teva Pharmaceuticals has announced the introduction and availability of Clopidogrel Tablets, an AB rated and bioequivalent product to Plavix Tablets (Bristol-Myers Squibb and Sanofi Aventis). Clopidogrel Tablets 75mg are available from Teva in 30, 90, and 500 count bottles.
Mylan Pharmaceuticals received approval to market Clopidogrel Tablets 75mg and 300mg. The 75mg tablet will be supplied in bottle form and unit dose packs of 100, while the 300mg tablet will be available in unit dose packs of 30.
Dr. Reddy's has launched Clopidogrel Tablets 75mg and 300mg. The 75mg tablets are available in 30, 90, and 500 count bottles; the 300mg tablets are available in blister packs of 30-count.
Plavix, a platelet aggregation inhibitor, is indicated for:
- Acute coronary syndrome:
- For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)] including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.
-For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary PCI is unknown.
- Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.